Aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE)—rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease - 05/09/11
Doi : 10.1016/S0002-9149(00)00872-9
Jonathan L Isaacsohn, MD a, Michael H Davidson, MD b, Donald Hunninghake, MD c, Robert Singer, BS d, ⁎, Richard McLain, MS d, Donald M Black, MD d
a Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, USA
b Chicago Center for Clinical Research, Chicago, Illinois, USA
c Departments of Medicine and Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA
d Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan, USA
*Mr. Singer’s address is: Parke-Davis Pharmaceutical Research, 2800 Plymouth Road, Ann Arbor, Michigan 48105
 | This study is being sponsored by Parke-Davis Pharmaceutical Research, a Division of Warner Lambert Company, Ann Arbor, Michigan; and Pfizer Inc., New York, New York. |
© 2000
Excerpta Medica Inc. Reservados todos los derechos.
Vol 86 - N° 2
P. 250-252 - juillet 2000 Regresar al número
Artículo precedente
- Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus type 2
- Ursula Rauch, Jill Crandall, Julio I Osende, John T Fallon, James H Chesebro, Valentin Fuster, Juan J Badimon
- Aorto-left ventricular tunnel: transcatheter closure using an amplatzer duct occluder device
- Massimo Chessa, Milind Chaudhari, Joseph Vincent De Giovanni
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?